US · AUTL
Autolus Therapeutics plc
- Sector
- Healthcare · Biotechnology
- Headquarters
- London W12 7FP
- Website
- autolus.com
Price · as of 2024-12-31
$1.47
Market cap 455.11M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $67.14 | +4,467.35% |
| Intrinsic Value(DCF) | $1.15 | -21.77% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $3.19 | $0.00 | |||
| 2018 | $37.00 | $38.48 | $4.16 | $1.57 | $28.01 |
| 2019 | $8.25 | $42.04 | $0.00 | $0.00 | $0.00 |
| 2020 | $6.70 | $21.86 | $0.00 | $0.00 | $85.68 |
| 2021 | $3.98 | $23.59 | $1.98 | $0.00 | $6.98 |
| 2022 | $1.90 | $48.60 | $1.38 | $0.00 | $0.00 |
| 2023 | $5.71 | $30.23 | $0.00 | $0.00 | $73.45 |
| 2024 | $2.01 | $67.14 | $0.58 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Autolus Therapeutics plc's (AUTL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $67.14
- Current price
- $1.47
- AI upside
- +4,467.35%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.15
-21.77% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AUTL | Autolus Therapeutics plc | $1.47 | 455.11M | +4,467% | -22% | — | — | -2.32 | 1.20 | 50.68 | 0.10 | — | 1.24 | -1293.48% | -2385.63% | -2180.45% | -81.91% | 263.57% | -38.11% | 0.12 | -25.98 | 10.88 | 10.47 | 0.75 | -2750.00% | 49600.00% | 5398.00% | -47.01% | -3.40 | 263.21% | 0.00% | 0.00% | 0.00% | 0.09 | 0.09 | -2.23 | -1.19 |
| ADCT | ADC Therapeutics S.A. | $4.10 | 507.9M | +465% | -82% | — | — | -1.13 | -0.88 | 2.52 | -0.50 | — | -0.88 | 91.60% | -184.44% | -222.83% | 89.97% | 41.28% | -46.65% | -0.61 | -2.60 | 3.82 | 3.37 | 1.25 | -4490.00% | 184.00% | 230.00% | -69.75% | -1.54 | 39.40% | 0.00% | 0.00% | 0.00% | -0.39 | -0.41 | 0.72 | -6.56 |
| ANNX | Annexon, Inc. | $5.60 | 669.73M | — | — | — | — | -2.74 | 1.29 | — | -0.71 | — | 1.29 | 0.00% | — | — | -50.84% | -955.34% | -42.67% | 0.10 | — | 10.37 | 10.23 | 0.15 | -4294.00% | — | -273.00% | -31.12% | -3.87 | -731.80% | 0.00% | 0.00% | 0.00% | -0.62 | -0.82 | — | 0.68 |
| AURA | Aura Biosciences, Inc. | $5.89 | 374.03M | — | — | — | — | -4.23 | 2.42 | — | -2.48 | — | 2.42 | 0.00% | — | — | -46.01% | -494.17% | -39.73% | 0.12 | — | 10.77 | 10.13 | 0.14 | -933.00% | — | 2556.00% | -22.06% | -5.35 | -416.75% | 0.00% | 0.00% | 0.00% | -2.45 | -2.90 | — | 3.57 |
| BNTC | Benitec Biopharma Inc. | $10.90 | 286.09M | — | — | — | — | -13.28 | 5.18 | — | -9.76 | — | 5.18 | 0.00% | — | — | -52.46% | 2846.97% | -49.96% | 0.01 | — | 54.67 | 54.26 | 2.32 | -6082.00% | — | 2055.00% | -4.69% | -13.09 | 1609.13% | 0.00% | 0.00% | 9.20% | -9.74 | -17.23 | — | 128.14 |
| LBRX | LB Pharmaceuticals Inc Co… | $24.01 | 607.43M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 97.81% | 65.95% | -159.37% | -0.04 | — | 3.56 | 3.45 | 0.31 | 90734.00% | — | 34410.00% | — | -6.54 | 54.75% | — | 0.00% | — | — | — | — | — |
| NMRA | Neumora Therapeutics, Inc… | $3.49 | 583.14M | — | — | — | — | -0.97 | 0.83 | — | 0.26 | -36.29 | 0.83 | 0.00% | — | — | -64.48% | -31666.35% | -59.96% | 0.01 | — | 10.51 | 10.29 | 0.53 | 268.00% | — | 1196.00% | -77.03% | -6.12 | -21987.50% | 0.00% | 0.00% | 0.00% | 0.26 | 0.37 | — | -1.09 |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| RAPT | RAPT Therapeutics, Inc. | $57.98 | 958.84M | — | — | — | — | -0.35 | 0.24 | — | 1.34 | -7.75 | 0.24 | 0.00% | — | — | -77.09% | 654.65% | -62.79% | 0.02 | — | 4.87 | 4.78 | 1.22 | 458.00% | — | -1503.00% | -181.11% | -1.72 | 401.25% | 0.00% | 0.00% | 270.67% | 1.33 | 2.16 | — | -3.97 |
| RCKT | Rocket Pharmaceuticals, I… | $5.01 | 542.19M | — | — | — | — | -2.48 | 1.99 | — | -2.38 | — | 2.59 | 0.00% | — | — | -60.27% | -135.95% | -52.00% | 0.09 | -122.55 | 6.38 | 2.57 | 0.25 | -2637.00% | — | -1166.00% | -34.48% | -6.29 | -111.72% | 0.00% | 0.00% | 0.00% | -2.16 | -2.62 | — | -1.60 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
- CEO
- Christian Martin Itin
- Employees
- 647
- Beta
- 1.99
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.15 ÷ $1.47) − 1 = -21.77% (DCF, example).